NCT01329627

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Instituto do Cancer do Estado de São Paulo · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.

Conditions

• Locally Advanced HER2-negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel/doxorubicin/cyclophosphamide	Metronomic chemotherapy as described below: 1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; 2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
DRUG	Paclitaxel/doxorubicin/cyclophosphamide	Metronomic chemotherapy as described below: Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-08-01
• Completion: 2012-08-01
• First posted: 2011-04-06
• Last updated: 2014-05-21

Locations

1 site across 1 country: Brazil